11 Best Genomics Stocks to Buy According to Hedge Funds

Page 3 of 10

8. 10x Genomics, Inc. (NASDAQ:TXG)

Number of Hedge Fund Holders: 35

Revenue growth (YoY): -1.28%

10x Genomics, Inc. (NASDAQ:TXG) has announced a global settlement agreement with Bruker Corporation, which resolves all outstanding patent litigation between the two firms.

As per the agreement, from Q3 2025 to Q2 2026, Bruker will pay 10x Genomics, Inc. (NASDAQ:TXG) $68 million in equal quarterly installments. Furthermore, Bruker will pay continuous royalties on sales of spatial biology products for the duration of the licensed patents. Global patent cross-licenses and the termination of all legal actions in the United States, Germany, and the European Unified Patent Court are part of the settlement.

10x Genomics, Inc. (NASDAQ:TXG), a leader in single-cell and spatial biology, pointed out the need for intellectual property protection to promote scientific innovation. CEO Serge Saxonov regarded the outcome as a validation of the company’s vision and dedication to innovation.

Eric Whitaker, Chief Legal Officer, noted the robustness of the firm’s IP portfolio and its fundamental function in spatial biology. The settlement makes it possible to keep funding upcoming innovations. It is among the Best Genomics Stocks.

Page 3 of 10